IMR Press / FBL / Special Issues / 1326789577385869313

Tumor antigens: from spontaneous immune response in cancer patients to cancer vaccines

Submission deadline: 31 January 2022
Special Issue Editors
  • Roberto Bei, MD
    Department of Clinical Sciences and Translational Medicine, University of Rome, Tor Vergata, Rome, 00133 Italy,Center for Regenerative Medicine, (CIMER), University of Rome “Tor Vergata”, Rome, 00133 Italy
    Interests: Oncology: analysis of immune response to tumor associated antigens in cancer patients and cancer immunotherapy; Analysis of the expression of tumor antigens in tumors and normal tissues; Effect of natural compounds on cancer cell growth
  • Laura Masuelli
    Department of Experimental Medicine, University of Rome "Sapienza"
    Interests: Cancer Immunotherapy and Anti-cancer Drugs
Special Issue Information

Dear Colleagues,

The aim of specific active cancer immunotherapy is to stimulate the host's immune response against cancer cells through direct immune system stimulation using a platform carrying one or more tumor antigens (TAs). The outcome of the cancer vaccine should be the recognition of the cancer cell-expressed TAs by specific immune effectors. Thus, the identification of TAs is crucial for the development of effective cancer vaccines. TAs can be divided into tumor-specific antigens (TSAs), that are unique antigens expressed by tumor cells and not by normal cells, and tumor-associated antigens (TAAs), which are also expressed by normal cells although at lower levels than in tumor cells. TAs include mutated antigens, oncofetal antigens (OFs), cancer-testis antigens (CTs), aberrantly glycosylated and expressed antigens, tissue lineage antigens, overexpressed antigens and virally-encoded antigens. The purpose of this special issue is to collect research articles or review that emphasize the role of the humoral and cellular immune response against tumor antigens including neoantigens to mediate tumor rejection. In addition, studies and reviews of cancer vaccines targeting Tumor Antigens are welcome.

Prof. Roberto Bei and Assoc. Prof. Laura Masuelli

Guest Editor

Tumor Antigens
Immune Response
Cancer Vaccine
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (3 Papers)
Back to top